Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans

Por Carlile, David J, Hakooz, Nancy, Bayliss, Martin K, Houston, J Brian
Publicado em 1999

Population pharmacokinetics of the MEK inhibitor selumetinib and its active N‐desmethyl metabolite: data from 10 phase I trials

Por Patel, Parul, Howgate, Eleanor, Martin, Paul, Carlile, David J., Aarons, Leon, Zhou, Diansong
Publicado no Br J Clin Pharmacol (2017)

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

Por Cartron, Guillaume, Hourcade-Potelleret, Florence, Morschhauser, Franck, Salles, Gilles, Wenger, Michael, Truppel-Hartmann, Anna, Carlile, David J.
Publicado no Haematologica (2016)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis

Por Dymond, Angela W., Elks, Cathy, Martin, Paul, Carlile, David J., Mariani, Gabriella, Lovick, Susan, Huang, Yifan, Lorch, Ulrike, Brown, Helen, So, Karen
Publicado no Eur J Clin Pharmacol (2017)

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Por Byrd, John C., Flynn, Joseph M., Kipps, Thomas J., Boxer, Michael, Kolibaba, Kathryn S., Carlile, David J., Fingerle-Rowson, Guenter, Tyson, Nicola, Hirata, Jamie, Sharman, Jeff P.
Publicado no Blood (2016)

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Cli...

Por Jänne, Pasi A., van den Heuvel, Michel M., Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crinò, Lucio, Orlov, Sergey, Blackhall, Fiona, Wolf, Juergen, Garrido, Pilar, Poltoratskiy, Artem, Mariani, Gabriella, Ghiorghiu, Dana, Kilgour, Elaine, Smith, Paul, Kohlmann, Alexander, Carlile, David J., Lawrence, David, Bowen, Karin, Vansteenkiste, Johan
Publicado no JAMA (2017)